BRAF Kinase Inhibitors Market
- 2026 年市場規模
- USD 2.12 Bn
- 2033 年預估規模
- USD 3.52 Bn
- 年複合成長率 CAGR
- 8.3%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
BRAF Kinase Inhibitors Market, By Drug (Vemurafenib, Dabrafenib, Lifirafenib, Encorafenib), By Indication (Metastatic Melanoma, Metastatic Lung Cancer, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
報告摘要
BRAF is a kinase enzyme that helps control cell growth and signalling. It may be found in a mutated (changed) form in some types of cancer, including melanoma and colorectal cancer. Blocking mutated BRAF kinase proteins may help keep cancer cells from growing. Some BRAF kinase inhibitors are used to treat cancer. About 50 % of melanomas harbors activating BRAF mutations (over 90 % V600E). BRAFV600E has been implicated in different mechanisms underlying melanomagenesis, most of which due to the deregulated activation of the downstream MEK/ERK effectors. Two compounds (vemurafenib and dabrafenib) have achieved approval by the Food and Drug Administration (FDA) for the treatment of metastatic and unresectable BRAF-mutated melanomas.
Market Dynamics
Key players in the BRAF kinase inhibitors market are focusing on obtaining patents, which is expected to create more opportunities for BRAF kinase inhibitor drugs manufacturers in the emerging economies. For instance, in September 2016, Novartis International AG secured an Indian patent for its skin cancer (melanoma) drug Tafinlar, which is used for the treatment of metastatic melanoma, the most serious and life-threatening type of skin cancer that is associated with low survival rates.
However, one of the challenges in BRAF kinase inhibitors market is patient adherence. Due to the high cost of BRAF kinase inhibitor drugs, patients are shifting from the actual treatment regime to alternatives of cancer treatments. Alternative methods available for cancer treatments is expected to hinder growth of the BRAF kinase inhibitors market in the near future. For instance, metastatic cancer requires systemic therapy or medications given through mouth or injected into the bloodstream to reach cancer cells throughout the body such as chemotherapy or hormone therapy. Other treatments may include immunotherapy, radiation therapy, surgery or a combination of these.
Key features of the study
• This report provides in-depth analysis of the global BRAF kinase inhibitors market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period: 2020-2027, considering 2019 as the base year
• It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles key players in the global BRAF kinase inhibitors market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, and strategies
• Key players covered as a part of this study include F. Hoffmann-La Roche AG, Novartis International AG, and Pfizer, Inc.
• Insights from this report would allow marketers and management authorities of companies to make informed decisions with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The global BRAF kinase inhibitors market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for BRAF kinase inhibitors market, research and consulting firms, new entrants, and financial analysts.
Market Segmentation
• By Drug
o Vemurafenib
o Dabrafenib
o Lifirafenib
o Encorafenib
• By Indication
o Metastatic Melanoma
o Metastatic Lung Cancer
o Others
• By Distribution Channel
o Hospital Pharmacies
o Retail Pharmacies
o Online Pharmacies
• By Region
o North America
U.S.
Canada
o Latin America
Brazil
Mexico
Argentina
Rest of Latin America
o Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
South Africa
Central Africa
North Africa
• Key Players
o Hoffmann-La Roche Ltd.
o Novartis AG
o Array BioPharma Inc. (Pfizer)
o Bayer AG
o Plexxikon Inc. (Daiichi Sankyo)
o Blueprint Medicines
o Kinnate Biopharma Inc.
o IDEAYA Biosciences
o Mirati Therapeutics
o Loxo Oncology (Eli Lilly)
o BeiGene Ltd.
o Spectrum Pharmaceuticals
o Ono Pharmaceutical
o Chugai Pharmaceutical
o BridgeBio Pharma
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Purview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Drug
Market Snapshot, By Indication
Market Snapshot, By Distribution Channel
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Product Approval
o Collaboration/Merge/Acquisition
o Regulatory Landscape
o PEST Analysis
o Porter’s Five Forces Analysis
o Epidemiology
o Robust Pipeline Analysis
4. Global BRAF Kinase Inhibitors Market, By Drug, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Vemurafenib
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Dabrafenib
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Lifirafenib
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Encorafenib
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
5. Global BRAF Kinase Inhibitors Market, By Indication, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Metastatic Melanoma
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Metastatic Lung Cancer
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
6. Global BRAF Kinase Inhibitors Market, By Distribution Channel, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022 – 2033
Segment Trends
o Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
o Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021–2033, (USD Billion)
7. Global BRAF Kinase Inhibitors Market, By Region, 2021 – 2033, (USD Billion)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2022–2033
Regional Trends
o North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Billion)
o GCC
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Drug, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Indication, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (USD Billion)
Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 – 2033, (USD Billion)
o North Africa
o Central Africa
o South Africa
8. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
o Company Profile
F. Hoffmann-La Roche Ltd.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Novartis AG
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Array BioPharma Inc. (Pfizer)
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Bayer AG
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Plexxikon Inc. (Daiichi Sankyo)
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Blueprint Medicines
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Kinnate Biopharma Inc.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
IDEAYA Biosciences
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Mirati Therapeutics
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Loxo Oncology (Eli Lilly)
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
BeiGene Ltd.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Spectrum Pharmaceuticals
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Ono Pharmaceutical
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Chugai Pharmaceutical
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
BridgeBio Pharma
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Analyst Views
9. Section
o References
o Research Methodology
o About Us
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們